Cumberland Pharmaceuticals' Phase 2 trial shows ifetroban improves heart function in Duchenne muscular dystrophy patients.

Cumberland Pharmaceuticals’ Duchenne muscular dystrophy (DMD) drug has improved the amount of blood pumped by the heart, ...

NASHVILLE, Tenn. - Cumberland Pharmaceuticals Inc. (NASDAQ: NASDAQ:CPIX), a specialty pharmaceutical company with a market ...

The Elevate-44-201 study is a global, two-part, randomized, double-blind placebo-controlled phase 1/2 study evaluating the ...

BOSTON - Entrada Therapeutics , Inc. (NASDAQ:TRDA) received authorization from the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) to initiate a Phase 1/2 clinical trial for its ...

Contrary to prior data, this study shows that neither eosinophils nor STAT6-mediated IL-4/IL-13 signaling contribute ...

Facebook parent Meta Platforms Inc. is replacing fact checking on the platform with a feature called Community Notes, Chief Executive Mark Zuckerberg announced Tuesday in rolling out a raft of ...

Advances in Duchenne, MPS, or wet AMD ... The company is trading for roughly the cash on its balance sheet. The RGX-121 program is presently the furthest in development. REGENXBIO is pushing ...

Last week, Meta Platforms (NASDAQ: META) said that it is shutting down the third-party fact-checking programs on its social media platforms. Chief Executive Officer Mark Zuckerberg says that those ...

There is a simple discount patient access scheme for vamorolone. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...